News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
792,639 Results
Type
Article (77353)
Company Profile (690)
Press Release (714596)
Section
Business (214891)
Career Advice (3682)
Deals (38012)
Drug Delivery (126)
Drug Development (88217)
Employer Resources (183)
FDA (17521)
Job Trends (16756)
News (370797)
Policy (36875)
Tag
2024 BioCapital Digital (20)
2024 BioForest Digital (16)
2024 BioForest Standard (1)
2024 BioMidwest Digital (14)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (19)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (19)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (10)
2024 Genetown Standard (12)
2024 Lone Star Bio Digital (17)
2024 Pharm Country Digital (13)
2024 Pharm Country Standard (7)
2025 BioForest Digital (13)
2025 Lone Star Bio Digital (16)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (2985)
Academic (2)
Accelerated approval (3)
Adcomms (29)
Allergies (87)
Alliances (53086)
ALS (92)
Alzheimer's disease (1468)
Antibody-drug conjugate (ADC) (138)
Approvals (17490)
Artificial intelligence (269)
Autoimmune disease (20)
Automation (14)
Bankruptcy (369)
Best Places to Work (12625)
BIOSECURE Act (21)
Biosimilars (113)
Biotechnology (475)
Bladder cancer (65)
Brain cancer (28)
Breast cancer (268)
Cancer (2144)
Cardiovascular disease (185)
Career advice (3122)
Career pathing (33)
CAR-T (160)
Cell therapy (450)
Cervical cancer (20)
Clinical research (70931)
Collaboration (833)
Compensation (462)
Complete response letters (30)
COVID-19 (2831)
CRISPR (43)
C-suite (231)
Cystic fibrosis (105)
Data (2002)
Decentralized trials (2)
Denatured (39)
Depression (50)
Diabetes (272)
Diagnostics (6846)
Digital health (18)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (124)
Drug pricing (121)
Drug shortages (33)
Duchenne muscular dystrophy (92)
Earnings (84489)
Editorial (39)
Employer branding (23)
Employer resources (157)
Events (125416)
Executive appointments (681)
FDA (18687)
Featured Employer (59)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (744)
Gene editing (110)
Generative AI (27)
Gene therapy (322)
GLP-1 (816)
Government (5038)
Grass and pollen (4)
Guidances (48)
Healthcare (20833)
Huntington's disease (23)
IgA nephropathy (25)
Immunology and inflammation (128)
Indications (27)
Infectious disease (2977)
Inflammatory bowel disease (147)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (90)
Interviews (709)
IPO (17672)
IRA (50)
Job creations (4635)
Job search strategy (2565)
Kidney cancer (9)
Labor market (34)
Layoffs (534)
Leadership (20)
Legal (8885)
Liver cancer (76)
Lung cancer (314)
Lymphoma (137)
Machine learning (4)
Management (62)
Manufacturing (302)
MASH (67)
Medical device (14501)
Medtech (14506)
Mergers & acquisitions (20836)
Metabolic disorders (721)
Multiple sclerosis (74)
NASH (23)
Neurodegenerative disease (98)
Neuropsychiatric disorders (31)
Neuroscience (1997)
NextGen: Class of 2025 (7596)
Non-profit (5067)
Northern California (2481)
Now hiring (37)
Obesity (393)
Opinion (269)
Ovarian cancer (75)
Pain (89)
Pancreatic cancer (79)
Parkinson's disease (142)
Partnered (21)
Patents (219)
Patient recruitment (97)
Peanut (51)
People (63511)
Pharmaceutical (142)
Pharmacy benefit managers (21)
Phase I (22004)
Phase II (30885)
Phase III (23239)
Pipeline (1073)
Podcasts (116)
Policy (135)
Postmarket research (3238)
Preclinical (9763)
Press Release (72)
Prostate cancer (99)
Psychedelics (38)
Radiopharmaceuticals (267)
Rare diseases (400)
Real estate (6991)
Recruiting (72)
Regulatory (25094)
Reports (42)
Research institute (2643)
Resumes & cover letters (582)
Rett syndrome (3)
RNA editing (4)
RSV (46)
Schizophrenia (76)
Series A (132)
Series B (84)
Service/supplier (29)
Sickle cell disease (56)
Southern California (2168)
Special edition (18)
Spinal muscular atrophy (164)
Sponsored (33)
Startups (3980)
State (2)
Stomach cancer (16)
Supply chain (66)
The Weekly (74)
United States (22571)
Vaccines (752)
Venture capitalists (39)
Webinars (13)
Weight loss (287)
Women's health (37)
Worklife (18)
Date
Today (247)
Last 7 days (748)
Last 30 days (2935)
Last 365 days (36195)
2025 (8595)
2024 (37851)
2023 (42502)
2022 (53838)
2021 (58673)
2020 (57625)
2019 (51243)
2018 (38964)
2017 (36125)
2016 (36480)
2015 (42390)
2014 (36799)
2013 (34152)
2012 (34716)
2011 (34892)
2010 (34197)
Location
Africa (1134)
Alabama (55)
Alaska (7)
Arizona (226)
Arkansas (14)
Asia (46458)
Australia (8303)
California (5789)
Canada (1899)
China (508)
Colorado (260)
Connecticut (283)
Delaware (136)
Europe (107832)
Florida (844)
Georgia (205)
Hawaii (1)
Idaho (64)
Illinois (575)
India (27)
Indiana (314)
Iowa (10)
Japan (146)
Kansas (106)
Kentucky (27)
Louisiana (11)
Maine (68)
Maryland (897)
Massachusetts (4494)
Michigan (234)
Minnesota (398)
Mississippi (2)
Missouri (85)
Montana (31)
Nebraska (26)
Nevada (58)
New Hampshire (69)
New Jersey (1659)
New Mexico (31)
New York (1652)
North Carolina (1071)
North Dakota (8)
Northern California (2481)
Ohio (205)
Oklahoma (15)
Oregon (47)
Pennsylvania (1294)
Puerto Rico (10)
Rhode Island (29)
South America (1495)
South Carolina (19)
South Dakota (1)
Southern California (2168)
Tennessee (95)
Texas (878)
Utah (175)
Virginia (151)
Washington D.C. (65)
Washington State (562)
West Virginia (3)
Wisconsin (63)
792,639 Results for "the new england journal of medicine".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OpenEvidence Achieves $1 Billion Valuation in Sequoia-led Round and Announces Content Partnership with the New England Journal of Medicine
February 19, 2025
·
4 min read
Press Releases
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
February 5, 2025
·
13 min read
Press Releases
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
February 7, 2025
·
15 min read
Press Releases
New England Journal of Medicine publishes new data for Roche’s Gazyva/Gazyvaro which shows superiority over standard therapy in people with active lupus nephritis
February 7, 2025
·
12 min read
Press Releases
New England Journal of Medicine Publishes Results of Global, Multicenter eNRGy Study Evaluating Zenocutuzumab-zbco (BIZENGRI®) in NRG1+ cancer
February 5, 2025
·
10 min read
Biotech Beach
Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine
Oncocyte Corporation, a precision diagnostics company, announced that favorable data regarding its lead product VitaGraft™ Kidney was published in the New England Journal of Medicine.
May 30, 2024
·
8 min read
Press Releases
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
November 27, 2024
·
5 min read
Drug Development
Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine(NEJM) has published results from a positive Phase 3 trial for Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE).
June 26, 2024
·
22 min read
Press Releases
Data Published Today in the New England Journal of Medicine Demonstrates Anthos Therapeutics’ novel Factor XI inhibitor, Abelacimab 150mg, Reduced Major or Clinically Relevant Non-Major Bleeding by 62% Compared to Rivaroxaban (Xarelto) in Patients with Atrial Fibrillation
January 23, 2025
·
7 min read
Drug Development
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase 3 study investigating crinecerfont for the treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency have been published in The New England Journal of Medicine online edition and will appear in a future print issue of the journal.
June 3, 2024
·
11 min read
1 of 79,264
Next
